Trial reportScientific reports2026
Improved muscle recovery after omega-3 supplementation is associated with increased oxylipin availability.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Eccentric exercise-induced muscle damage (EIMD) impairs muscle function and recovery. While omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation has shown promise in mitigating EIMD, the role of their oxidation products (oxylipins) remains unclear. This study investigated the effects of 8-week n-3 PUFA supplementation on muscle recovery and its relationship with blood oxylipin profiles after EIMD in healthy men. Eighteen participants were randomly assigned into two groups: OMEGA (n = 9 28.0 ± 2.5 y; 2.5 g/d of DHA and 0.5 g/d of EPA) and PLACEBO (n = 9 21.4 ± 0.6 y; maltodextrin). Participants performed one bout of 100 unilateral isokinetic eccentric maximal voluntary contractions of the knee extensor muscles before and after an 8-week supplementation period. N-3 PUFA supplementation augmented plasma EPA- and DHA-derived oxylipins (p < 0.05) in the OMEGA group, which showed an attenuation of peak muscle maximum voluntary contraction loss (-15.4 ± 5.2%; p = 0.05) post-exercise compared to the PLACEBO group (1.3 ± 6.0%). There were no differences in muscles soreness between groups. Multivariate analyses identified body fat percentage and specific n-3 and n-6 PUFA-derived oxylipins as predictors of MVC loss after EIMD. In conclusion, the increased plasma levels of n-3 PUFA derived oxylipins following supplementation suggest a possible role for these lipid mediators in promoting muscle recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.